Sirolimus inhibits the mTOR signaling pathway, a therapeutic target in vascular lesions associated with APS nephropathy [79,80,81], and appears promising in CAPS, but there is currently insufficient data to recommend its use. The gene discussed is MTOR; the disease is cryopyrin-associated periodic syndrome.